Botulinum Toxin Market

Botulinum Toxin Market - Global
Insights, and Forecast till 2026
Industry
Botulinum toxin is a product produced by naturally occurring Clostridium botulinum bacteria.
This bacteria is found in soil and marine sediments and can produce harmful neurotoxin
botulinum toxin. Botulinum toxin is a ‘blocking agent’ which inhibits the release of certain
neurotransmitters, specifically acetylcholine, from the endings of the motor nerves. There are
about eight types of botulinum toxin named from type A to H. Botulinum toxin type A and
botulinum toxin type B are majorly used in cosmetic procedures for the treatment of various
facial conditions, its commercially marketed under the brand name Botox. Botulinum toxin type
A and B are also used in medical applications for treatment of various diseases such as
dystonia, chronic migraines, and spasticity.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1518
Botulinum Toxin Market: Drivers
Frequent approvals of novel botulinum toxin products for different indications are expected to
drive growth of the Botulinum Toxin Market in near future. For instance, in 2016, Ipsen S.A.
received the U.S. Food and Drug Administration (FDA) approval for its Dysport
(abobotulinumtoxinA) injection indicated for the treatment of pediatric lower limb (PLL)
spasticity in children of age two years and older. In 2017, company received the FDA approval
for same product to use in adults. In 2017, Allergan plc. received FDA approval for BOTOX
Cosmetic (OnabotulinumtoxinA) for new indication in forehead lines, and previously the product
has been approved for the treatment of , crow's feet lines, and glabellar lines. With this
approval company has expanded the indication of its product in the temporary improvement in
the appearance of moderate to severe forehead lines associated with frontalis muscle activity in
adults. In 2014, Allergan Inc. received approval for its BOTOX (Botulinum toxin type A) from
Medicines and Healthcare Products Regulatory Agency (MHRA) in U.K. BOTOX was approved in
the U.K. for treatment of ankle disability due to lower limb spasticity associated with stroke in
adults. In 2016, Daewoong Pharmaceutical Co., Ltd received approval for its botulinum toxin
Nabota in Mexico and India. Nabota was introduced by Daewoong Pharmaceutical Co., Ltd in
South Korea in 2014. In 2015, Merz North America, the U.S. subsidiary of the global Merz
Pharma Group, received U.S. FDA approval for Xeomin (incobotulinumtoxinA) indicated for the
treatment of upper limb spasticity (ULS) in adult patients. Furthermore, increasing trend of
botulinum toxin in cosmetic procedures is also expected to increase the growth of Botulinum
Toxin Market in near future. For instance, according to a report published by American Society
of Plastic Surgeons in 2016, around 7,056,255 cosmetic minimally-invasive procedures were
performed with Botulinum toxin Type A (Botox, Dysport, and Xeomin), there was an increase of
4% in procedures as compared to 2015. Increasing number of procedures with botulinum toxin
along with increasing approved indication is expected to drive growth of the global Botulinum
Toxin Market.
Report includes chapters which deeply display the following deliverable about industry :
• Botulinum Toxin Market Research Objective and Assumption
• Botulinum Toxin Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Botulinum Toxin Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Botulinum Toxin Market, By Regions
• Botulinum Toxin Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Botulinum Toxin Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Botulinum Toxin Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Botulinum Toxin Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Botulinum Toxin Market: Regional analysis
North America is expected to hold a dominant position in the global botulinum toxin market,
owing to increasing trend of cosmetic procedures in the region. For instance, according to a
report published by American Society of Plastic Surgeons in 2016, around US$ 16.4 billion was
spent on cosmetic procedures in the U.S. and in 2017, around 7.2 million botulinum injections
were used in the U.S. for cosmetic procedures. Increasing number of cosmetic procedures in the
key region of North America is expected to drive the growth of the botulinum toxin market in
near future. Furthermore, Asia Pacific is expected to show rapid growth in botulinum toxin
market, owing to increasing R&D and approval of novel products in China. For instance, in
January 2018, Daewoong Pharmaceutical Co. Ltd., a Korean company, received approval from
the Chinese authorities to conduct clinical trials for botulinum toxin Nabota in China.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1518
Botulinum Toxin Market: Key Players
Key players operating in global botulinum toxin market includes Ipsen group, Allergan Plc.,
Medytox Inc., Merz GmbH and Co. KGaA, US Worldmed, LLC, Lanzhou Institute of Biological
Products Co. Ltd., Revance Therapeutics, Inc., and Daewoong Pharmaceutical Co., Ltd. Major
players in market are involved in strategic collaborations to develop new products. For instance,
in February 2018, Mylan N.V. and Revance Therapeutics, Inc. underwent strategic collaboration
and license agreement for the development and commercialization of a proposed biosimilar to
BOTOX (onabotulinumtoxinA). Furthermore, key players are focusing on receiving approvals of
its product in key market to expand their presence in global market. For instance, in February
2018, Medytox Inc. filed a new drug application with the China Food and Drug Administration
(CFDA) to its botulinum neurotoxin product Meditoxin in China.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Botulinum toxin is a product produced by naturally occurring Clostridium botulinum bacteria.

Download Report